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Introduction
Malignant otitis externa (MOE) is a rare aggressive, 
necrotizing infection of the external auditory 
canal and the temporal bone; it most commonly 
affects older patients, patients with diabetes, and/
or patients that are immunocompromised (e.g., due 
to AIDS, chemotherapy, rheumatologic conditions, 
or autoimmunity).1-10 Pseudomonas aeruginosa 
is the main agent involved in MOE pathogenesis, 
although other bacteria may be involved, such 
as Staphylococcus aureus, Klebsiella spp., and 
Aspergillus spp.110 MOE typically arises as an 
infection in the tissues of the ear canal at the bony-
cartilaginous junction. It spreads quickly to the 
surrounding tissues, then towards the temporal 
bone and skull base. The most frequent symptom of 
MOE is intense otalgia, which is often associated 
with temporal or occipital headache. Disease 
manifestations include painful inflammation of the 
external ear canal, associated with purulent otorrhea 
and granulated polyps. MOE is histologically 
identified by inflammatory cell infiltration and 
hyperplasia of the squamous epithelium.1-10 Three 
clinical stages have been described. The first stage 
is an infection of the external auditory canal and 
adjacent soft tissues with severe pain, with or 
without facial nerve palsy. The second stage is 
characterized by infection extension, with osteitis of 
the skull base and temporal bone, or multiple cranial 
nerve neuropathies. In the third stage, the infection 
reaches the intracranial structures, neck spaces, and 
large blood vessels.1-10 Achieving an early diagnosis 
is often difficult, because the clinical findings in 
the early stages of MOE are similar to those of 
classical external otitis. Diagnostic delays and the 
consequent lack of prompt, adequate treatment lead 
to successive evolution of the pathology.1-10 
 This study aimed to evaluate the management of 8 
cases of MOE, and to review the literature, focusing 
particularly on the staging and management of this 
disease.
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 The micro-otoscopic examinations disclosed, in 
5 cases, purulent otorrhea, with granulated tissue 
and cartilaginous segregation of the ear canal; in 
3 cases, the presence of a polypoid formation. In 
all cases, the tympanic membrane was thickened 
and hyperemic. One case presented a concomitant 
multiple cranial nerve palsy (VII, IX, XI, XII). 
All the microbiological examinations disclosed the 
presence of P. aeruginosa. 
 All patients underwent a temporal bone CT 
scan: all cases presented mastoid involvement and 
a thickening of the external auditory canal (EAC). 
Some bone erosion of the EAC was evidenced in 6 
patients; mandibular condyle erosion was observed 
in 2 subjects; and skull base osteomyelitis with 
Patients and methods
This retrospective study included 8 patients with 
MOE. All patients were evaluated and treated at the 
ENT & Audiology Department and at the Infectious 
Diseases Department of the University Hospital of 
Ferrara, from January 2012 to December 2016. For 
each patient, we collected all data concerning the 
clinical history, clinical examinations, laboratory 
data, microbiological findings, imaging, and 
treatment.
 Diagnosis of MOE was defined, based on (i) a 
clinical history of recurrent otitis externa or otitis 
resistant to therapies in patients with diabetes; (ii) 
isolation of P. aeruginosa in the microbiological 
examination of the aural discharge; and (iii) 
radiological signs of temporal bone involvement. 
All patients were treated for a median of 6 months. 
Therefore, follow-up was conducted in the 
subsequent months.
 This study was compliant with the Helsinki 
Declaration (2008). Informed consent was not 
required, due to the retrospective and observational 
design of this study, which did not affect patient 
care in any way. Nevertheless, all subjects were 
informed about the research project during the 
visits, and they all consented to participate in the 
study.
Results
Our series of patients with MOE were mostly 
male (7/8). The average age at diagnosis was 75.1 
(±5) years. Among the observed comorbidities, all 
patients had inadequately managed diabetes mellitus 
(HbA1c >8%). In all cases, the clinical history was 
characterized by a recurrent or persistent external 
otitis that had lasted at least one month, despite 
numerous attempted treatments. Patients were 
mainly treated with oral amoxicillin, associated 
with aural irrigation with antiseptic agents or 
topical antibiotics, such as aminoglycosides or 
fluoroquinolones. The main clinical features of the 
patients are shown in Table 1. 
 All patients complained of ear pain and purulent 
discharge at diagnosis. One patient also reported 
other symptoms, including nocturnal nuchal 
headache and progressive dysphagia. 
 The laboratory tests showed that 4/8 cases had 
ESR (Erythrocyte Sedimentation Rate) >140 mm 
and CRP (C-Reactive Protein) >110 mg/l. 
Table 1
Clinical features of patients with malignant otitis externa
DM: Diabetes Mellitus; COPD: chronic obstructive pulmonary 
disease.
Figure 1
Coronal (A,B,D) and axial (C,E) CT scans of cranial bone in a 
patient with malignant otitis externa. Cortical bone erosion (red 
arrows) is apparent in the left mastoid and the clivus.
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base osteomyelitis that involved the VII, IX, 
and X cranial nerves, exhibited an overlapping, 
invasive fungal infection (Aspergillus fumigatus). 
Intravenous voriconazole was administered (400 
mg every 12 h for the first day, followed by 200 
mg/day), prior to hospitalization in the Infectious 
Diseases Department. That patient experienced 
symptom remission after 1 month of treatment 
(although a grade III House-Brackmann facial 
nerve paralysis persisted). The other patient also 
received trans-tympanic drainage. 
 In all cases, the infection was controlled after a 
median of 6 months of therapy. All patients were 
followed-up for an average of 12 months after 
resolution of the infection. 
Discussion and Conclusion
MOE is thought to appear most commonly in 
individuals with diabetes mellitus; however, it can 
also occur in individuals with HIV infections, in 
those treated with immunosuppressive therapies, or 
in those affected by oncohematologic diseases.1 Its 
frequency has increased over time, and its prevalence 
has doubled in the last decade, probably due to the 
greater prevalence of (i) diabetes mellitus, and (ii) 
a longer life span, which has resulted in an older 
population.2 MOE mortality has not been correlated 
with age, gender, the degree of glucose tolerance, 
the duration of diabetes, the type of microorganism, 
comorbidities, or the involvement of a single cranial 
nerve. MOE mortality has mainly been correlated 
with the duration of hospitalization, surgical 
therapy (when performed), skull base involvement, 
the presence of intracranial extension, and multiple 
cranial nerve palsy.3,4 Adequate, prompt treatment 
has always been advocated. Levenson proposed 
clinical criteria for diagnosing MOE, including: 
refractory otitis externa, severe nocturnal otalgia, 
purulent otorrhea, the presence of granulated 
tissue in the external auditory canal, growth of 
Pseudomonas, and the presence of diabetes mellitus 
or an immunocompromised state.5 In some cases, 
facial nerve palsy might also occur.6,7 P. aeruginosa 
is the most commonly isolated microorganism, 
as found in the present study;8 however, in some 
cases, other microorganisms have been identified.8 
Invasive mycotic involvement should be suspected 
when the infection is resistant to antipseudomonal 
treatment, when the culture examinations are 
negative, and when patients carry HIV.9 In these 
clivus erosion was observed in 2 cases. In one 
case, cortical erosion of the mastoid bone was also 
observed (Figure 1). MRI scans were performed 
only in selected cases.
 Therapeutic procedures are summarized in Table 
2. In most cases, a combination of antibiotics 
was administered. The goals of the therapeutic 
strategies (Table 3) were: (i) to control diabetes 
mellitus adequately; (ii) to debride necrotic tissue 
periodically, with micro-otoscopic guidance and 
with local antiseptic solutions; and (iii) to provide 
systemic and topical antimicrobial therapies, with 
high-dose fluoroquinolone (ciprofloxacin 500 or 
750 mg every 12 h) for at least 2 weeks. Patients also 
received systemic administration of a high-dose, 
third-generation cephalosporin (i.e., cefditoren 
400 mg every 12 h) for at least 15 days, usually 
in combination with ciprofloxacin. Three patients 
that were resistant to therapy were hospitalized and 
given intravenous carbapenems or third-generation 
cephalosporins. 
 A surgical approach was required for two 
patients that did not respond to medical treatment. 
One case, which was complicated with skull 
Table 2
Therapeutic procedures performed in patients with malignant 
otitis externa
Table 3
Therapeutic strategies adopted for 8 patients with 
malignant otitis externa
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 When the initial clinical and neuroradiological 
evaluations (Figure 2) produce findings of 
local or neurological complications, prompt 
hospitalization is necessary to facilitate daily 
micro-otoscopic debridement and a strict clinical 
follow-up (in particular, monitoring glycemia). 
When no improvement is observed after 2 weeks 
of targeted antimicrobial therapy, the ear swab 
should be repeated, and based on analytical 
findings, the antimicrobial treatment should be 
adjusted. Furthermore, after 6/8 weeks from the 
initial assessment, another neuroradiological 
assessment should be performed (Figure 2). The 
role of hyperbaric therapy in MOE management 
remains to be defined; however, it should be 
used in combination with antimicrobial therapy.21 
According to the most recent findings in the 
literature, surgery has limited value (Figure 2); 
some authors have indicated that surgery promoted 
the spread of infection through fascial and vascular 
planes or to healthy bone, which worsened the 
prognosis.4,6 A surgical approach is indicated 
in cases of antimicrobial therapy failure, deep 
local debridement, cartilaginous/bony sequestrum 
removal, abscess drainage, or suspected neoplastic 
lesions (i.e., ear canal squamous cell carcinoma).22,23 
Therefore, in our experience, the management of 
MOE should always involve an infectious disease 
specialist and a neuroradiologist. Both can play 
important roles in informing a correct diagnosis and 
evaluating treatment responses, in collaboration 
with the ENT specialist.
cases, surgical debridement of necrotic tissue in 
the external auditory canal should be followed 
by a deep tissue biopsy. This biopsy is essential 
for histopathological confirmation of an invasive 
fungal infection.6,10 Aspergillus spp. is the most 
commonly involved mycete, in these cases.6,10
 A temporal bone CT scan is always necessary to 
evaluate bone erosion of the ear canal, as indicated 
previously by several authors.6,11,12 A conventional 
MRI allows an examination of surrounding soft 
tissue involvement and the detection of skull 
base inflammatory involvement or intracranial 
complications.13 Al-Noury and Lotfy evaluated 18 
cases of MOE. An examination of temporal bone CTs 
disclosed persistent bone erosion in all 18 patients. 
Moreover, temporal bone MRIs showed that 60% 
of patients had soft tissue alterations and 33% had 
bone marrow anomalies that persisted for 1 year.14 
Cherko et al, used MRI with diffusion weighted 
imaging (DWI), for a radiological follow-up of 
patients with MOE.15 Other reports have indicated 
that scintigraphy with radiopharmaceuticals, such 
as Gallium-67 citrate, or leukocyte labeling with 
HMPAO-Tc99 or Sulesomab-Tc99, showed high 
diagnostic specificity for MOE; in some cases, 
these approaches were also used in clinical follow-
ups.1,16,17
 Currently, specific guidelines for MOE manage-
ment and treatment have not been established in the 
literature. Based on our experience, and considering 
the data available in the literature, we propose 
a diagnostic-therapeutic flow-chart for MOE 
treatment (Figure 2). As suggested previously, 
the first therapeutic approach should be medical 
treatment. Patients typically receive strict diabetes 
mellitus monitoring and treatment with a high oral 
dose of fluoroquinolones, such as ciprofloxacin. 
Fluoroquinolones are useful, due to their low 
toxicity and high ability to reach bone tissue. 
However, microbial resistance to those classes 
of antibiotics has been described; consequently, 
many authors have proposed carbapenem or third-
generation cephalosporins, such as ceftazidime or 
cefditoren.5,18,19 Long-term use of aminoglycosides 
can lead to nephrotoxicity and ototoxicity.20 
However, voriconazole or amphotericin B has been 
suggested for treating overlapping Aspergillus 
infections.6,10 ,12 An emerging problem is the 
appearance of antibiotic resistance in Pseudomonas 
spp. and other Gram-negative bacteria. Thus, 
antibiotic use should be carefully managed. 
Figure 2
Proposed diagnostic and therapeutic flow-chart for patients 
with malignant otitis externa (MOE)
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 We recommend that clinical randomized studies 
of large series should be performed in the near future 
to clarify the best medical and surgical approaches 
for treating this insidious pathology.
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